Century Therapeutics, Inc. (IPSC) Misses Q2 EPS by 4c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.34 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
• Semtech (SMTC) Tops Q2 EPS by 10c, Beats on Revenue; Offers Q3 Guidance
• Morgan Stanley Double Downgrades Gujarat Energy (GUJENERG:IN) to Underweight